Anchor Investment Management LLC Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Anchor Investment Management LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,347 shares of the medical research company's stock after buying an additional 4,623 shares during the quarter. Anchor Investment Management LLC's holdings in Edwards Lifesciences were worth $3,061,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. raised its stake in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after buying an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its stake in Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after acquiring an additional 300,000 shares during the period. Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $4,845,000. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the sale, the vice president now directly owns 47,206 shares in the company, valued at $3,295,450.86. This represents a 16.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 over the last 90 days. Corporate insiders own 1.29% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent analyst reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Truist Financial lowered their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $78.55.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.36 on Friday, hitting $71.56. 3,235,636 shares of the stock were exchanged, compared to its average volume of 4,927,071. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The firm's 50 day moving average is $71.31 and its two-hundred day moving average is $70.85. The firm has a market capitalization of $42.07 billion, a PE ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.